Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | Director | June 03, 2026 | June 05, 2026 |
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | Director | June 04, 2024 | June 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,300 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 35,500 · Balance 48,300 F1: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2036-06-03 | Direct | 53,250 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Grant · Acquired 53,250 · Balance 53,250 F2: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
F2: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Tvardi Therapeutics, Inc.
Report date June 04, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 198,485 |
Reported balance
After 2024-06-04 transaction · row 1
1 source rowRow 1 · 2024-06-04 · Grant · Acquired 150,647 · Balance 198,485 F1: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2034-06-04 | Direct | 195,000 |
Reported balance
After 2024-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-04 · Grant · Acquired 195,000 · Balance 195,000 F2: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
F2: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 20:29 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 53,250 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001628280-26-041270 · wk-form4_1780691363.xml · derivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,250 Underlying: Common Stock · 53,250 shares Expires 2036-06-03 F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:29 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-041270 · wk-form4_1780691363.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,300 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:52 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001576885-25-000079 · wk-form4_1749156704.xml · derivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2035-06-04 F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:52 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 12,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-25-000079 · wk-form4_1749156704.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,800 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 10, 2024 Filed Jun 10, 2024 20:54 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001576885-24-000086 · wk-form4_1718052886.xml · derivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 10, 2025 or the 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:25 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001415889-24-015760 · form4-06062024_080636.xml · derivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2034-06-04 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:25 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 150,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015760 · form4-06062024_080636.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,485 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 22:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionStock Option (right to buy) · Derivative | 2,800 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001576885-23-000052 · wk-form4_1692397878.xml · derivative · entry 6 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,800 shares Expires 2031-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 22:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionStock Option (right to buy) · Derivative | 39,149 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001576885-23-000052 · wk-form4_1692397878.xml · derivative · entry 5 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,149 shares Expires 2029-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 22:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 2,800 | $6.66 | $18,648.00 |
DisclosureSEC source: 0001576885-23-000052 · wk-form4_1692397878.xml · nonDerivative · entry 4 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on May 17, 2023. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 22:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionCommon Stock | 2,800 | $1.19 | $3,332.00 |
DisclosureSEC source: 0001576885-23-000052 · wk-form4_1692397878.xml · nonDerivative · entry 3 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 22:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 39,149 | $6.48 | $253,685.52 |
DisclosureSEC source: 0001576885-23-000052 · wk-form4_1692397878.xml · nonDerivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on May 17, 2023. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 22:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | Exercise / conversionCommon Stock | 39,149 | $0.72 | $28,187.28 |
DisclosureSEC source: 0001576885-23-000052 · wk-form4_1692397878.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 21:43 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001576885-23-000034 · wk-form4_1686174166.xml · derivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 6, 2024 or the 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:33 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 44,961 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001209191-23-034327 · doc4.xml · derivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,961 Underlying: Common Stock · 44,961 shares Expires 2033-06-01 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:33 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 32,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034327 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,838 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 21:16 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,600 | $9.05 | $32,580.00 |
DisclosureSEC source: 0001209191-22-042606 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,476 F1 · kind: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on June 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.97 to $9.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:25 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001209191-22-037881 · doc4.xml · derivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:51 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 16,996 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001209191-22-034626 · doc4.xml · derivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,996 Underlying: Common Stock · 16,996 shares Expires 2032-06-02 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 2, 2023 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:51 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 11,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034626 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,076 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 2, 2023 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 23:15 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 8,180 | $16.04 | $131,207.20 |
DisclosureSEC source: 0001209191-21-064855 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,200 Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:18 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044949 · doc4.xml · derivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control. Read SEC document |
| June 07, 2021 Filed Jun 7, 2021 23:25 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,520 | $13.05 | $32,886.00 |
DisclosureSEC source: 0001209191-21-038760 · doc4.xml · nonDerivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,380 F2 · shares: Represents the number of shares sold by the Reporting Person to satisfy the Reporting Person's tax obligations resulting from the settlement of vested RSUs on June 3, 2021. The sales were effected pursuant to a "sell-to-cover" arrangement adopted in accordance with Rule 10b5-1 on May 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.02 to $13.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:25 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 10,800 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0001209191-21-038760 · doc4.xml · derivative · entry 3 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2031-06-03 F4 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:25 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 7,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038760 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,900 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| November 19, 2020 Filed Nov 24, 2020 01:26 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 2,500 | $15.75 | $39,372.50 |
DisclosureSEC source: 0001209191-20-060096 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,700 Read SEC document |
| November 19, 2020 Filed Nov 24, 2020 22:46 UTC Amendment | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,500 | $15.75 | $39,372.50 |
DisclosureSEC source: 0001209191-20-060288 · doc4a.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,700 Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 21:47 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 10,800 | $0.00 Strike: $15.62 | $0.00 |
DisclosureSEC source: 0001209191-20-035065 · doc4.xml · derivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2030-06-04 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 21:47 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 7,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035065 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2021 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 23:51 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $9.94 | $0.00 |
DisclosureSEC source: 0001209191-20-034312 · doc4.xml · derivative · entry 3 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2025-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 23:51 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 1,000 | $16.00 | $16,000.00 |
DisclosureSEC source: 0001209191-20-034312 · doc4.xml · nonDerivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 23:51 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 1,000 | $9.94 | $9,940.00 |
DisclosureSEC source: 0001209191-20-034312 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:02 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $9.94 | $0.00 |
DisclosureSEC source: 0001209191-20-029396 · doc4.xml · derivative · entry 3 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 2,500 shares Expires 2025-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:02 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001209191-20-029396 · doc4.xml · nonDerivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:02 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 2,500 | $9.94 | $24,850.00 |
DisclosureSEC source: 0001209191-20-029396 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| April 21, 2020 Filed Apr 21, 2020 23:09 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $9.94 | $0.00 |
DisclosureSEC source: 0001209191-20-025311 · doc4.xml · derivative · entry 3 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 2,500 shares Expires 2025-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| April 21, 2020 Filed Apr 21, 2020 23:09 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001209191-20-025311 · doc4.xml · nonDerivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| April 21, 2020 Filed Apr 21, 2020 23:09 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 2,500 | $9.94 | $24,850.00 |
DisclosureSEC source: 0001209191-20-025311 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:39 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $9.94 | $0.00 |
DisclosureSEC source: 0001209191-20-016942 · doc4.xml · derivative · entry 3 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 2,500 shares Expires 2025-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:39 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001209191-20-016942 · doc4.xml · nonDerivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:39 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 2,500 | $9.94 | $24,850.00 |
DisclosureSEC source: 0001209191-20-016942 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:01 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $9.94 | $0.00 |
DisclosureSEC source: 0001209191-20-006976 · doc4.xml · derivative · entry 3 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 2,500 shares Expires 2025-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:01 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,500 | $16.23 | $40,575.00 |
DisclosureSEC source: 0001209191-20-006976 · doc4.xml · nonDerivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:01 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 2,500 | $9.94 | $24,850.00 |
DisclosureSEC source: 0001209191-20-006976 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:06 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $9.94 | $0.00 |
DisclosureSEC source: 0001209191-20-002081 · doc4.xml · derivative · entry 3 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 2,500 shares Expires 2025-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:06 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,500 | $16.13 | $40,325.00 |
DisclosureSEC source: 0001209191-20-002081 · doc4.xml · nonDerivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:06 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 2,500 | $9.94 | $24,850.00 |
DisclosureSEC source: 0001209191-20-002081 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:49 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $5.32 | $0.00 |
DisclosureSEC source: 0001209191-19-059181 · doc4.xml · derivative · entry 3 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:49 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,500 | $25.83 | $64,575.00 |
DisclosureSEC source: 0001209191-19-059181 · doc4.xml · nonDerivative · entry 2 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:49 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 2,500 | $5.32 | $13,300.00 |
DisclosureSEC source: 0001209191-19-059181 · doc4.xml · nonDerivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and subsequent sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 15, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.